Temozolomide and Pituitary Tumors : Current Understanding, Unresolved Issues, and Future Directions

ABSTRACT: Temozolomide, an alkylating agent, initially used in the treatment of gliomas was expanded to include pituitary tumors in 2006. After 12 years of use, temozolomide has shown a notable advancement in pituitary tumor treatment with a remarkable improvement rate in the 5-year overall survival...

Full description

Autores:
Syro Moreno, Luis Vicente
Rotondo, Fabio
Camargo Guerrero, Mauricio
Ortíz Gómez, León Darío
Serna Ortíz, Carlos Andrés
Kovacs, Kalman
Tipo de recurso:
Review article
Fecha de publicación:
2018
Institución:
Universidad de Antioquia
Repositorio:
Repositorio UdeA
Idioma:
eng
OAI Identifier:
oai:bibliotecadigital.udea.edu.co:10495/20366
Acceso en línea:
http://hdl.handle.net/10495/20366
https://www.frontiersin.org/articles/10.3389/fendo.2018.00318/full
Palabra clave:
Agentes alquilantes
Alkylating Agents
Antineoplastic Agents
Antineoplásicos
Reparación del ADN
DNA Repair
Neoplasias
Neoplasms
Tumores Neuroendocrinos
Neuroendocrine Tumors
O(6)-Methylguanine-DNA Methyltransferase
O(6)-Metilguanina-ADN Metiltransferasa
Neoplasias Hipofisarias
Pituitary Neoplasms
Temozolomida
Temozolomide
Metiltransferasa
Methyltransferases
Quimioterapia
Chemotherapy
Rights
openAccess
License
http://creativecommons.org/licenses/by/2.5/co/
id UDEA2_7853b6a2954c7858ea5366c32da02569
oai_identifier_str oai:bibliotecadigital.udea.edu.co:10495/20366
network_acronym_str UDEA2
network_name_str Repositorio UdeA
repository_id_str
dc.title.spa.fl_str_mv Temozolomide and Pituitary Tumors : Current Understanding, Unresolved Issues, and Future Directions
title Temozolomide and Pituitary Tumors : Current Understanding, Unresolved Issues, and Future Directions
spellingShingle Temozolomide and Pituitary Tumors : Current Understanding, Unresolved Issues, and Future Directions
Agentes alquilantes
Alkylating Agents
Antineoplastic Agents
Antineoplásicos
Reparación del ADN
DNA Repair
Neoplasias
Neoplasms
Tumores Neuroendocrinos
Neuroendocrine Tumors
O(6)-Methylguanine-DNA Methyltransferase
O(6)-Metilguanina-ADN Metiltransferasa
Neoplasias Hipofisarias
Pituitary Neoplasms
Temozolomida
Temozolomide
Metiltransferasa
Methyltransferases
Quimioterapia
Chemotherapy
title_short Temozolomide and Pituitary Tumors : Current Understanding, Unresolved Issues, and Future Directions
title_full Temozolomide and Pituitary Tumors : Current Understanding, Unresolved Issues, and Future Directions
title_fullStr Temozolomide and Pituitary Tumors : Current Understanding, Unresolved Issues, and Future Directions
title_full_unstemmed Temozolomide and Pituitary Tumors : Current Understanding, Unresolved Issues, and Future Directions
title_sort Temozolomide and Pituitary Tumors : Current Understanding, Unresolved Issues, and Future Directions
dc.creator.fl_str_mv Syro Moreno, Luis Vicente
Rotondo, Fabio
Camargo Guerrero, Mauricio
Ortíz Gómez, León Darío
Serna Ortíz, Carlos Andrés
Kovacs, Kalman
dc.contributor.author.none.fl_str_mv Syro Moreno, Luis Vicente
Rotondo, Fabio
Camargo Guerrero, Mauricio
Ortíz Gómez, León Darío
Serna Ortíz, Carlos Andrés
Kovacs, Kalman
dc.contributor.researchgroup.spa.fl_str_mv Genética Regeneración y Cáncer
dc.subject.decs.none.fl_str_mv Agentes alquilantes
Alkylating Agents
Antineoplastic Agents
Antineoplásicos
Reparación del ADN
DNA Repair
Neoplasias
Neoplasms
Tumores Neuroendocrinos
Neuroendocrine Tumors
O(6)-Methylguanine-DNA Methyltransferase
O(6)-Metilguanina-ADN Metiltransferasa
Neoplasias Hipofisarias
Pituitary Neoplasms
Temozolomida
Temozolomide
Metiltransferasa
Methyltransferases
topic Agentes alquilantes
Alkylating Agents
Antineoplastic Agents
Antineoplásicos
Reparación del ADN
DNA Repair
Neoplasias
Neoplasms
Tumores Neuroendocrinos
Neuroendocrine Tumors
O(6)-Methylguanine-DNA Methyltransferase
O(6)-Metilguanina-ADN Metiltransferasa
Neoplasias Hipofisarias
Pituitary Neoplasms
Temozolomida
Temozolomide
Metiltransferasa
Methyltransferases
Quimioterapia
Chemotherapy
dc.subject.lemb.none.fl_str_mv Quimioterapia
Chemotherapy
description ABSTRACT: Temozolomide, an alkylating agent, initially used in the treatment of gliomas was expanded to include pituitary tumors in 2006. After 12 years of use, temozolomide has shown a notable advancement in pituitary tumor treatment with a remarkable improvement rate in the 5-year overall survival and 5-year progression-free survival in both aggressive pituitary adenomas and pituitary carcinomas. In this paper, we review the mechanism of action of temozolomide as alkylating agent, its interaction with deoxyribonucleic acid repair systems, therapeutic effects in pituitary tumors, unresolved issues, and future directions relating to new possibilities of targeted therapy.
publishDate 2018
dc.date.issued.none.fl_str_mv 2018
dc.date.accessioned.none.fl_str_mv 2021-06-25T01:51:12Z
dc.date.available.none.fl_str_mv 2021-06-25T01:51:12Z
dc.type.spa.fl_str_mv Artículo de revisión
dc.type.coar.fl_str_mv http://purl.org/coar/resource_type/c_2df8fbb1
dc.type.coar.spa.fl_str_mv http://purl.org/coar/resource_type/c_dcae04bc
dc.type.redcol.spa.fl_str_mv https://purl.org/redcol/resource_type/ARTREV
dc.type.coarversion.spa.fl_str_mv http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.driver.spa.fl_str_mv info:eu-repo/semantics/article
dc.type.version.spa.fl_str_mv info:eu-repo/semantics/publishedVersion
format http://purl.org/coar/resource_type/c_dcae04bc
status_str publishedVersion
dc.identifier.uri.none.fl_str_mv http://hdl.handle.net/10495/20366
dc.identifier.doi.none.fl_str_mv 10.3389/fendo.2018.00318
dc.identifier.eissn.none.fl_str_mv 1664-2392
dc.identifier.url.spa.fl_str_mv https://www.frontiersin.org/articles/10.3389/fendo.2018.00318/full
url http://hdl.handle.net/10495/20366
https://www.frontiersin.org/articles/10.3389/fendo.2018.00318/full
identifier_str_mv 10.3389/fendo.2018.00318
1664-2392
dc.language.iso.spa.fl_str_mv eng
language eng
dc.relation.ispartofjournalabbrev.spa.fl_str_mv Front. Endocrinol.
dc.relation.citationendpage.spa.fl_str_mv 14
dc.relation.citationissue.spa.fl_str_mv 1
dc.relation.citationstartpage.spa.fl_str_mv 1
dc.relation.citationvolume.spa.fl_str_mv 9
dc.relation.ispartofjournal.spa.fl_str_mv Frontiers in Endocrinology
dc.rights.uri.*.fl_str_mv http://creativecommons.org/licenses/by/2.5/co/
dc.rights.uri.spa.fl_str_mv https://creativecommons.org/licenses/by/4.0/
dc.rights.accessrights.spa.fl_str_mv info:eu-repo/semantics/openAccess
dc.rights.coar.spa.fl_str_mv http://purl.org/coar/access_right/c_abf2
rights_invalid_str_mv http://creativecommons.org/licenses/by/2.5/co/
https://creativecommons.org/licenses/by/4.0/
http://purl.org/coar/access_right/c_abf2
eu_rights_str_mv openAccess
dc.format.extent.spa.fl_str_mv 14
dc.format.mimetype.spa.fl_str_mv application/pdf
dc.publisher.spa.fl_str_mv Frontiers Media
dc.publisher.place.spa.fl_str_mv Lausana, Suiza
institution Universidad de Antioquia
bitstream.url.fl_str_mv https://bibliotecadigital.udea.edu.co/bitstreams/9065b993-c954-4146-ae1a-959bf195d36e/download
https://bibliotecadigital.udea.edu.co/bitstreams/ef5cb386-88fc-4636-a513-d81faf08f9fe/download
https://bibliotecadigital.udea.edu.co/bitstreams/30f5af6b-c8f5-4037-8f97-c0378ce1d456/download
https://bibliotecadigital.udea.edu.co/bitstreams/e90b8a1d-892d-4590-8304-c9bab64cc854/download
https://bibliotecadigital.udea.edu.co/bitstreams/a574a24d-710b-4dbc-883c-375d77473ec2/download
bitstream.checksum.fl_str_mv 21e65ab96e31e76337191c5c39e2f609
8a4605be74aa9ea9d79846c1fba20a33
1646d1f6b96dbbbc38035efc9239ac9c
799fe5f3fcb2ac13572ab55a11a56d27
ef4c7cc2581a8b1818ac4f3cdcac649e
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
MD5
MD5
repository.name.fl_str_mv Repositorio Institucional de la Universidad de Antioquia
repository.mail.fl_str_mv aplicacionbibliotecadigitalbiblioteca@udea.edu.co
_version_ 1851052618902667264
spelling Syro Moreno, Luis VicenteRotondo, FabioCamargo Guerrero, MauricioOrtíz Gómez, León DaríoSerna Ortíz, Carlos AndrésKovacs, KalmanGenética Regeneración y Cáncer2021-06-25T01:51:12Z2021-06-25T01:51:12Z2018http://hdl.handle.net/10495/2036610.3389/fendo.2018.003181664-2392https://www.frontiersin.org/articles/10.3389/fendo.2018.00318/fullABSTRACT: Temozolomide, an alkylating agent, initially used in the treatment of gliomas was expanded to include pituitary tumors in 2006. After 12 years of use, temozolomide has shown a notable advancement in pituitary tumor treatment with a remarkable improvement rate in the 5-year overall survival and 5-year progression-free survival in both aggressive pituitary adenomas and pituitary carcinomas. In this paper, we review the mechanism of action of temozolomide as alkylating agent, its interaction with deoxyribonucleic acid repair systems, therapeutic effects in pituitary tumors, unresolved issues, and future directions relating to new possibilities of targeted therapy.COL000676914application/pdfengFrontiers MediaLausana, Suizahttp://creativecommons.org/licenses/by/2.5/co/https://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccesshttp://purl.org/coar/access_right/c_abf2Temozolomide and Pituitary Tumors : Current Understanding, Unresolved Issues, and Future DirectionsArtículo de revisiónhttp://purl.org/coar/resource_type/c_dcae04bchttp://purl.org/coar/resource_type/c_2df8fbb1https://purl.org/redcol/resource_type/ARTREVhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionAgentes alquilantesAlkylating AgentsAntineoplastic AgentsAntineoplásicosReparación del ADNDNA RepairNeoplasiasNeoplasmsTumores NeuroendocrinosNeuroendocrine TumorsO(6)-Methylguanine-DNA MethyltransferaseO(6)-Metilguanina-ADN MetiltransferasaNeoplasias HipofisariasPituitary NeoplasmsTemozolomidaTemozolomideMetiltransferasaMethyltransferasesQuimioterapiaChemotherapyFront. Endocrinol.14119Frontiers in EndocrinologyPublicationORIGINALCamargoMauricio_2018_TomozolomidePituitaryTumors.pdfCamargoMauricio_2018_TomozolomidePituitaryTumors.pdfArtículo de revisiónapplication/pdf1579158https://bibliotecadigital.udea.edu.co/bitstreams/9065b993-c954-4146-ae1a-959bf195d36e/download21e65ab96e31e76337191c5c39e2f609MD51trueAnonymousREADLICENSElicense.txtlicense.txttext/plain; charset=utf-81748https://bibliotecadigital.udea.edu.co/bitstreams/ef5cb386-88fc-4636-a513-d81faf08f9fe/download8a4605be74aa9ea9d79846c1fba20a33MD53falseAnonymousREADCC-LICENSElicense_rdflicense_rdfapplication/rdf+xml; charset=utf-8927https://bibliotecadigital.udea.edu.co/bitstreams/30f5af6b-c8f5-4037-8f97-c0378ce1d456/download1646d1f6b96dbbbc38035efc9239ac9cMD52falseAnonymousREADTEXTCamargoMauricio_2018_TomozolomidePituitaryTumors.pdf.txtCamargoMauricio_2018_TomozolomidePituitaryTumors.pdf.txtExtracted texttext/plain81915https://bibliotecadigital.udea.edu.co/bitstreams/e90b8a1d-892d-4590-8304-c9bab64cc854/download799fe5f3fcb2ac13572ab55a11a56d27MD54falseAnonymousREADTHUMBNAILCamargoMauricio_2018_TomozolomidePituitaryTumors.pdf.jpgCamargoMauricio_2018_TomozolomidePituitaryTumors.pdf.jpgGenerated Thumbnailimage/jpeg14558https://bibliotecadigital.udea.edu.co/bitstreams/a574a24d-710b-4dbc-883c-375d77473ec2/downloadef4c7cc2581a8b1818ac4f3cdcac649eMD55falseAnonymousREAD10495/20366oai:bibliotecadigital.udea.edu.co:10495/203662025-03-27 01:09:51.369http://creativecommons.org/licenses/by/2.5/co/open.accesshttps://bibliotecadigital.udea.edu.coRepositorio Institucional de la Universidad de Antioquiaaplicacionbibliotecadigitalbiblioteca@udea.edu.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

Publicaciones similares